Prepared By:

Suraj Chaudhary
PGP10058
About Company
• Founded in 2014, Headquarters: Israel
• Co-founders-Eyal Gura, Elad Benjamin, and Eyal Toledano
• Developed algorithms that produced diagnoses from X-rays, mammograms,
and CT-scans. It will be able to flag critical cases earlier
• In 2014, formed a partnership with Clalit, the largest of Israel’s four HMOs
• Top 50 Fortune’s companies leading AI revolution
Competitive Advantage
• First mover advantage to collaborate with Clalit health service and get access to lot of data
• Location advantage, Herzliya they were able to attract people from Facebook, Apple and Google
• Oxford university research found that Zebra software
• Sensitivity Rate - 95%, giving false negative for 1 out of 20
• Specificity Rate – 100% with no false positives
• Global presence Europe, the US and India
• $1 per scan they need 6-7 big or 40-50 smaller hospitals to make real money and they already have a
base of 10,000 hospitals
• In 2018 they have been granted a clearance for their AI algorithm used to determine risk factors of
coronary heart disease
• 7/18 seven algorithms to analyze scans for liver density, bone density, brain bleeds, breast cancer, etc.
• Charged $1 to encourage care providers to use afford their tech
• Zebra tools could help prioritize who needs immediate help
Challenges
• Developing an algorithm to detect Tuberculosis as there is a data issue
• Many doctors do not have time to learn new designs and process so they have to produce simple to
use tools
• Different products for different origins
• Data has to be of high quality

Future Plans
• Shift focus on acute problems and cancer diagnoses
• Expansion to China, Australia, New Zealand and Singapore
• Have started experimentation with unsupervised learning for AI
• Achieve more accuracy
• Plan is to hire product managers and try to speed up the regulatory process